Reckitt Benckiser Group plc
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Reckitt Benckiser Group plc (Reckitt) manufactures and markets a broad portfolio of health, hygiene and nutrition consumer products worldwide; operates through Hygiene, Health and Nutrition segments; and sells brands including Dettol antiseptic and hygiene products, Lysol disinfectants, Harpic toilet cleaners, Finish dishwashing detergents, Air Wick air fresheners, Nurofen pain relief, Gaviscon indigestion remedies, Strepsils throat lozenges, Mucinex cough medicines, Durex contraceptives, Veet hair removal, Enfamil and Nutramigen infant nutrition formulas, Airborne vitamins and supplements, and Neuriva cognitive health products. The company maintains manufacturing facilities and operations in around 60 countries, with products distributed in nearly 200 markets, targeting households, families and healthcare consumers across developed and emerging regions. Founded through the 1999 merger of Reckitt & Colman plc and Benckiser N.V., with origins tracing to 1823 and 1840 respectively, Reckitt is headquartered in Slough, United Kingdom, and lists on the London Stock Exchange under ticker RKT.L. Reckitt pursues a focused strategy emphasizing 11 high-growth Powerbrands in health and hygiene, while streamlining its portfolio through divestitures of non-core assets. In July 2025, the company agreed to divest its Essential Home business—encompassing air care (Air Wick), surface care (Cillit Bang, Harpic), pest control (Mortein) and laundry care (Calgon, Woolite) brands generating approximately £2.0 billion in 2024 net revenue—to Advent International for up to US$4.8 billion enterprise value, retaining a 30% equity stake; the transaction, expected to complete by December 31, 2025, pending regulatory approvals, will enable a special dividend of about US$2.2 billion to shareholders alongside ongoing share buybacks and cost efficiencies targeting a fixed-cost base of 19% of net revenue by 2027. Recent trading updates reflect like-for-like net revenue growth of 7.0% in Q3 2025, driven by core health and hygiene momentum.
Company News
UBS says early flu pick-up could lift 2027 earnings at Reckitt and Haleon
How a Western Consumer Giant Is Thriving on China's Social-Media Shoppers
Reckitt Benckiser Group PLC (OTCMKTS:RBGLY) Receives Average Recommendation of “Moderate Buy” from Analysts
Reckitt Benckiser Group (OTCMKTS:RBGLY) Shares Gap Up – Time to Buy?
Reckitt faces mixed broker forecasts ahead of third-quarter update
Reckitt Benckiser Group (OTCMKTS:RBGLY) Share Price Breaks Below Two Hundred Day Moving Average – What’s Next?
Lysol and Mucinex Maker Reckitt Expands U.S. Manufacturing
Reckitt Benckiser Group PLC (OTCMKTS:RBGLY) Given Average Recommendation of “Moderate Buy” by Analysts
Reckitt Benckiser Group plc (RBGLY) Presents at Barclays 19th Annual Global Consumer Staples Conference Transcript
Reckitt Benckiser shares rise over 4% as JP Morgan upgrades to 'overweight'
3 Cheap International Stocks to Buy
First Bellwether Trial Today Against Reckitt Benckiser's Mead Johnson in NEC Baby Formula MDL Led by Levin Papantonio
Reckitt Announces Expiration and Results of Any and All Tender Offer and Consent Solicitation for Mead Johnson Nutrition Company Notes due 2044
Reckitt Announces Expiration and Results of Any and All Tender Offer and Consent Solicitation for Mead Johnson Nutrition Company Notes due 2044
Reckitt Benckiser: Core Brands Remain Undervalued Despite Mead Johnson Litigation Risk
Reckitt Benckiser Group: A Solid Quarter Supports The Investment Case
Reckitt Benckiser Group plc (RBGLY) Q2 2026 Earnings Call Transcript
Reckitt Benckiser Group H1 Earnings Call Highlights
Lysol Maker Reckitt Issues New $664 Million Share Buyback
Reckitt launches £500m buyback as quarterly sales accelerate